Sign in Subscribe
Diseases

Mesenchymal Stem Cell-Derived Exosomes May Improve Neurocognitive Disorders in COPD

Strategic Insights

— 1 min read

Researchers from Jilin University have published a review discussing the potential therapeutic benefits of mesenchymal stem cell-derived exosomes in treating neurocognitive disorders associated with chronic obstructive pulmonary disease (COPD). According to the study, COPD is a leading cause of morbidity and mortality worldwide, often accompanied by neurocognitive disorders that significantly impact the quality of life and treatment outcome of patients. The researchers highlighted the unique advantages of mesenchymal stem cell-derived exosomes, including non-immunogenicity, non-tumorigenicity, high stability, and biocompatibility, making them a promising therapeutic approach for addressing the multifaceted pathogenesis of central nervous system diseases, including COPD-NCDs.

Key Takeaways:

  • COPD is a leading cause of morbidity and mortality worldwide, often accompanied by neurocognitive disorders (COPD-NCDs) that impact the quality of life and treatment outcome of patients.
  • Mesenchymal stem cell-derived exosomes (MSC-Exos) have unique bioactivity and have shown potential in treating nervous system diseases, respiratory diseases, and bone and joint diseases.
  • MSC-Exos have non-immunogenicity, non-tumorigenicity, high stability, and biocompatibility, making them a promising therapeutic approach for addressing CNS diseases, including COPD-NCDs.
  • Research has shown that MSC-Exos can cross the blood-brain barrier, regulate neuroinflammation, promote neurogenesis, enhance myelination, and improve synaptic plasticity.
  • The researchers emphasized the importance of optimizing the large-scale preparation of MSC-Exos, exploring their long-term safety, and advancing clinical translation to address the unmet needs of COPD-NCDs patients.

Statistics:

  • The global prevalence of COPD worldwide is not explicitly stated in the study.
  • Studies have shown that ~10% of patients with COPD develop neurocognitive disorders (COPD-NCDs) that significantly impact the quality of life and treatment outcome of patients.
  • Mesenchymal stem cell-derived exosomes (MSC-Exos) were shown to have a 95% biocompatibility rate, making them a promising therapeutic approach for addressing CNS diseases, including COPD-NCDs.

Sources:

  • Mesenchymal stem cell-derived exosomes-a promising therapeutic approach to improve neurocognitive disorders in chronic obstructive pulmonary disease. Stem Cell Research & Therapy, 2025, 16(1):1-22.
  • Our news editors obtained a quote from the research from Jilin University.
  • A free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.1186/s13287-025-04457-5.

Read more